Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infections

被引：4

作者：

Nawar, Tamara ^{[1
]}

Kanafani, Zeina A. ^{[1
]}

机构：

[1] Amer Univ Beirut, Med Ctr, Dept Internal Med, Div Infect Dis, Beirut, Lebanon

来源：

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2015年 / 13卷 / 07期

关键词：

complicated skin and skin structure infection; lipoglycopeptide; methicillin-resistant S; aureus; telavancin; vancomycin; SOFT-TISSUE INFECTIONS; IN-VITRO ACTIVITY; STAPHYLOCOCCUS-AUREUS INFECTIONS; VANCOMYCIN-INTERMEDIATE; STANDARD THERAPY; BACTERICIDAL ACTIVITY; PHARMACOKINETICS; LIPOGLYCOPEPTIDE; EFFICACY; SAFETY;

D O I：

10.1586/14787210.2015.1043889

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Methicillin-resistant Staphylococcusaureus has emerged as a major causative pathogen in complicated skin and skin structure infections (cSSSIs). Unfortunately, treatment failure with vancomycin has been increasingly reported. Over the past decade, several alternative antimicrobial agents have been studied and approved for the treatment of cSSSIs. One such agent is the lipoglycopeptide telavancin, which was approved by the US FDA 2009. Given its dual mechanism of action, telavancin is characterized by a highly bactericidal activity and low potential for resistance selection. In addition, in clinical trials, it was efficacious and safe in the treatment of cSSSI. The purpose of this review is to give a background overview of telavancin, highlighting its microbiological, pharmacokinetic and pharmacodynamics characteristics, to summarize the available evidence for its use in the treatment of cSSSIs, and to provide an updated evaluation of its safety profile.

引用

页码：825 / 833

页数：9

共 61 条

[21] Activity of Telavancin against Staphylococci and Enterococci Determined by MIC and Resistance Selection Studies [J].

Kosowska-Shick, Klaudia ;

Clark, Catherine ;

Pankuch, Glenn A. ;

McGhee, Pamela ;

Dewasse, Bonifacio ;

Beachel, Linda ;

Appelbaum, Peter C. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (10) :4217-4224

[22] In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies [J].

Krause, Kevin M. ;

Barriere, Steven L. ;

Kitt, Michael M. ;

Benton, Bret M. .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2010, 68 (02) :181-185

[23] Treatment Failure and Costs in Patients With Methicillin-Resistant Staphylococcus aureus (MRSA) Skin and Soft Tissue Infections: A South Texas Ambulatory Research Network (STARNet) Study [J].

Labreche, Matthew J. ;

Lee, Grace C. ;

Attridge, Russell T. ;

Mortensen, Eric M. ;

Koeller, Jim ;

Du, Liem C. ;

Nyren, Natalie R. ;

Trevino, Lucina B. ;

Trevino, Sylvia B. ;

Pena, Joel ;

Mann, Michael W. ;

Munoz, Abilio ;

Marcos, Yolanda ;

Rocha, Guillermo ;

Koretsky, Stella ;

Esparza, Sandra ;

Finnie, Mitchell ;

Dallas, Steven D. ;

Parchman, Michael L. ;

Frei, Christopher R. .

JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2013, 26 (05) :508-517

[24] Hydrophobic vancomycin derivatives with improved ADME properties: Discovery of telavancin (TD-6424) [J].

Leadbetter, MR ;

Adams, SM ;

Bazzini, B ;

Fatheree, PR ;

Karr, DE ;

Krause, KM ;

Lam, BMT ;

Linsell, MS ;

Nodwell, MB ;

Pace, JL ;

Quast, K ;

Shaw, JP ;

Soriano, E ;

Trapp, SG ;

Villena, JD ;

Wu, TX ;

Christensen, BG ;

Judice, JK .

JOURNAL OF ANTIBIOTICS, 2004, 57 (05) :326-336

[25] Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) [J].

Leonard, Steven N. ;

Szeto, Yong G. ;

Zolotarev, Maria ;

Grigoryan, Ilona V. .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2011, 37 (06) :558-561

[26]

Lewis J S., 2022, Performance Standards for Antimicrobial Susceptibility Testing

[27] Telavancin Pharmacokinetics and Pharmacodynamics in Patients with Complicated Skin and Skin Structure Infections and Various Degrees of Renal Function [J].

Lodise, T. P. ;

Butterfield, J. M. ;

Hegde, S. S. ;

Samara, E. ;

Barrier, S. L. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (04) :2062-2066

[28] Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity [J].

Lodise, Thomas P. ;

Lomaestro, Ben ;

Graves, Jeffrey ;

Drusano, G. L. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (04) :1330-1336

[29] Acute renal insufficiency during telavancin therapy in clinical practice [J].

Marcos, Luis A. ;

Camins, Bernard C. ;

Ritchie, David J. ;

Casabar, Ed ;

Warren, David K. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (03) :723-726

[30] Telavancin In Vitro Activity against a Collection of Methicillin-Resistant Staphylococcus aureus Isolates, Including Resistant Subsets, from the United States [J].

Mendes, Rodrigo E. ;

Sader, Helio S. ;

Flamm, Robert K. ;

Farrell, David J. ;

Jones, Ronald N. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (03) :1811-1814

← 1 2 3 4 5 6 7 →